---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-23-000067"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2023-06-21T23:59:59+00:00"
generated_at: "2026-06-13T20:08:24.944034+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allogene reports updated Phase 1 data for ALLO-501/501A in r/r LBCL with 58% ORR and 42% CR

## Summary
- In 33 CAR T-naïve patients, ORR 58%, CR 42%; 30% maintained CR at 6 months across all patients.
- Phase 2 regimen (12 patients): ORR 67%, CR 58%; median duration of response 23.1 months.
- No Grade ≥3 CRS, no ICANS or GvHD; cytopenia and infections manageable, comparable to autologous CAR T.
- Company expects to complete enrollment of potentially pivotal Phase 2 ALPHA2 trial in 1H2024; plans to open sites in Europe, Canada, Australia in 2023.

## SEC filing metadata
- accession: 0001737287-23-000067
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2023-06-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000067/0001737287-23-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728723000067/allo-20230615.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-23-000067
- JSON: https://secwatch.observer/filing/0001737287-23-000067.json
- Plain text: https://secwatch.observer/filing/0001737287-23-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.